James E. Thompson

Emergency Medicine
1508 Triple Crown Ct
St Charles, IL 60174

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications

An AI system to help scientists write expert-level empirical software.

An AI system to help scientists write expert-level empirical software.

Journal: Nature
Published: September 13, 2025

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.

Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.

Journal: Leukemia & lymphoma
Published: December 27, 2024

Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors.

Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors.

Journal: Journal of medicinal chemistry
Published: July 30, 2024

Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.

Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.

Journal: Leukemia research
Published: June 05, 2024

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 23, 2024

Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.

Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.

Journal: JAMA network open
Published: December 18, 2023

Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.

Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.

Journal: Vaccine
Published: November 29, 2023

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Journal: The Lancet. Oncology
Published: October 06, 2023

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

Journal: Blood cancer journal
Published: July 08, 2023

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.

Journal: Blood
Published: April 13, 2022

Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.

Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 08, 2022

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.

Journal: Investigational new drugs
Published: March 28, 2022
Showing 1-12 of 59

Last Updated: 09/26/2026